CLINICAL COURSE OF REACTIVE ARTHRITIS DEPENDING ON ADAMTS7 SERUM LEVELS
Abstract
Reactive arthritis (ReA) is an inflammatory joint disease that develops as a sequela of previous urogenital or intestinal infection. The clinical manifestations of the disease are heterogeneous, ranging from mild and self-limiting arthritis to persistent, chronic forms with structural joint damage. In recent years, considerable attention has been directed toward the identification of molecular biomarkers reflecting inflammation and tissue remodeling processes. One of these biomarkers is ADAMTS7, a metalloproteinase involved in extracellular matrix degradation, which plays a critical role in the pathogenesis of joint destruction.
Given its involvement in inflammatory cascades, ADAMTS7 may serve as a potential marker for assessing disease severity and prognosis in patients with ReA.
References
1. Akhmedov K. et al. Changes in the immune system with rheumatoid arthritis in the background of the influence of environmental factors of the external environment //International Journal of Advanced Science and Technology. – 2020. – Т. 29. – №. 5. – С. 1907–1917.
2. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737–44. [PubMed: 11025665]
3. Bode W. Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003:1–14.[PubMed: 14587278]
4. Buranova, S. N. "Akhmedov Kh. S., Razakova FS Cartilage oligomeric matrix protein (COMP) in early diagnosis of osteoarthritis." The Chinese Journal of Occupational Diseases of Labor and Health 7.39 (2021): 93-100.
5. Buranova, S. N. "Akhmedov Kh. S., Razakova FS The Importance of Treatment Aimed at the Dynamics of Cartilage Oligomer Matrix Protein (COMP) in Patients with the Knee Joint Osteoarthritis." American Journal of Medicine and Medical Sciences.-2021 11.2 (2021): 148-153.
6. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute 1997;89:1260–70. [PubMed: 9293916]
7. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. The Journal of pathology 1999;189:300–8. [PubMed: 10547590]
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews 2002;2:161–74.
9. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884–9. [PubMed:10760260]
10. Khalmetova, F. I., X. S. Akhmedov, and G. A. Alibekova. "Features of the course of the joint syndrome in various forms of reactive arthritis." Galaxy International Interdisciplinary Research Journal 11.4 (2023): 832-837.
11. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl):S42–51. [PubMed: 10357558]
12. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4. [PubMed:10419448]
13. Rakhimova, M., et al. "Endothelin-1biomarker Features In Patients With Ankylosing Spondylitis After COVID-19." Journal of positive school psychology 6 (2022): 6.
14. Абдурахимов А.Г., Халметова Ф.И. Нестероидные противовоспалительные препараты у пациентов с деформирующим остеоартрозом и артериальной гипертензией: анализ влияния целекоксиба и мелоксикама на антигипертензивные средства. Оптимизация лечения. Атеросклероз. 2023;19(3):186-187. https://doi.org/10.52727/2078-256X-2023-19-3-186-187
